Generic Name and Formulations:
C1 inhibitor (human) 500 Units/vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.
Shire US, Inc.
Indications for CINRYZE:
Routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).
Give by IV infusion at a rate of 1mL/min (10mins). 1000 Units every 3–4 days.
Contains human plasma; monitor for possible infection transmission. Have epinephrine available to treat hypersensitivity reactions. Monitor patients with known risk factors for thrombotic events. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Upper respiratory tract infection, sinusitis, rash, headache; thrombotic events, hypersensitivity reactions (may be severe); discontinue if occurs.
To report infections that may have been transmitted by Cinryze, call CinryzeSolutions at (877) 945-1000.
Psychiatry Advisor Articles
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- No Evidence of Personality Changes Prior to Developing Cognitive Impairment, Dementia
- Retirement Saving Behavior Associated With Psychological Distress
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Physicians Spend Nearly 6 Hours on EHR Tasks Per Day
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder
- Enhanced Vaccination Effectiveness in Older Adults Linked to Positive Mood
- Subjective Cognitive Decline Linked to Alzheimer Biomarker
- Unnecessary Costs Associated With Low-Cost, Low-Value Health Services
- Is Hypertension Linked to an Increased Risk of Dementia?